Tedizolid Will Displace the Current Proprietary Clinical Gold Standard for cSSSIs, Teflaro, According to Findings from Decision Resources – Marketwatch

and due to thought leader concern over the high rate of quinolone resistance in MRSA and gram-negative pathogens. According to insights from surveyed U.S. infectious disease specialists and pharmacy and therapeutics committee members …